AGES:LSE:LSE-iShares IV Public Limited Company - iShares Ageing Population UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 576.875

Change

+2.88 (+0.50)%

Market Cap

USD 0.47B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.04 (-0.37%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

+4.50 (+2.37%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-1.28 (-0.91%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.08 (+0.42%)

USD 559.82B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.44%)

USD 500.71B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.70 (+1.06%)

USD 266.08B
0QZO:LSE 0QZO

+0.15 (+0.16%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.11 (+0.35%)

USD 204.07B
0QZ3:LSE Qualcomm Inc.

-4.06 (-2.34%)

USD 202.26B

ETFs Containing AGES:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.17% 46% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.17% 46% F 50% F
Trailing 12 Months  
Capital Gain 8.95% 43% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.95% 41% F 51% F
Trailing 5 Years  
Capital Gain 30.06% 48% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.06% 46% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 5.14% 55% F 60% D-
Dividend Return 5.14% 54% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.31% 55% F 70% C-
Risk Adjusted Return 38.62% 58% F 70% C-
Market Capitalization 0.47B 69% C- 59% D-

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike